吉利德科學公司將收購 Arcellx 的要約期限延長至四月下旬
Gilead Sciences extends offer to acquire Arcellx until late April
吉利德科學（ㄐㄧˊㄌㄧˋㄉㄜˊㄎㄜㄒㄩㄝ）公司已正式將其收購 Arcellx, Inc.
Gilead Sciences has officially extended its tender offer to acquire Arcellx, Inc. until April 24, 2026.
這項價值 78 億美元的重大交易，主要圍繞在收購一項研發中的 BCMA 導向 CAR-T 細胞療法 anito-cel，該療法旨在治療復發或難治性多發性骨髓瘤（ㄍㄨˇㄙㄨㄟˇㄌㄧㄡˊ）。
Under the offer terms, Gilead will pay $115 per share in cash, with an additional $5 contingent value right (CVR) if specific sales milestones for anito-cel are met by 2029.
根據要約條款，吉利德將以每股 115 美元的現金進行支付，並在 2029 年前若達成特定銷售里程碑，將額外支付 5 美元的或有價值權（CVR）。
This move allows Gilead to gain full control of the therapy, building on an existing partnership established in 2022.
透過整合 Arcellx，吉利德旨在強化其新一代細胞療法的產品組合。
While only about 7.5% of shares had been tendered by late March, the extension provides shareholders additional time to participate.
此次收購對吉利德在競爭激烈的多發性骨髓瘤治療領域邁出了重要的一步，並正展望其潛在的商業化前景。
